• Citer

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer.

par Burstein, Harold J;Sun, Yan;Dirix, Luc Y;Jiang, Zefei;Paridaens, R. ;Tan, Antoinette R;Awada, Ahmad ;Ranade, Anantbhushan;Jiao, Shunchang;Schwartz, Gary;Abbas, Richat;Powell, Christine;Turnbull, Kathleen;Vermette, Jennifer;Zacharchuk, Charles;Badwe, Rajendra
Référence Journal of clinical oncology, 28, 8, page (1301-1307)
Publication Publié, 2010-03

Article révisé par les pairs

• Détails
• Contenu

Titre:	Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer.
Auteur:	Burstein, Harold J; Sun, Yan; Dirix, Luc Y; Jiang, Zefei; Paridaens, R.; Tan, Antoinette R; Awada, Ahmad; Ranade, Anantbhushan; Jiao, Shunchang; Schwartz, Gary; Abbas, Richat; Powell, Christine; Turnbull, Kathleen; Vermette, Jennifer; Zacharchuk, Charles; Badwe, Rajendra
Informations sur la publication:	Journal of clinical oncology, 28, 8, page (1301-1307)
Statut de publication:	Publié, 2010-03
Sujet CREF:	Sciences bio-médicales et agricoles
Note générale:	Journal Article
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2009.25.8707
	info:pii/JCO.2009.25.8707
	info:pmid/20142587